Shopping Cart 0
Cart Subtotal
USD 0

Premenstrual Syndrome Treatment Market by Drug Type (Analgesics, Antidepressants, Oral Contraceptives & Ovarian Suppression Agents, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 8995

Details

The global premenstrual syndrome treatment market was valued at USD 1,129 million in 2018, and is projected to reach USD 1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026.
 
Premenstrual syndrome or PMS refers to physical & emotional symptoms, which occur one to two weeks before the initiation of woman's menses. It is characterized by symptoms such as acne, tender breasts, mood swings, bloating, fatigue, and irritability. Lifestyle changes are anticipated to help relieve PMS symptoms. However, based on the severity of symptoms, different types of drugs such as analgesics, antidepressants, and diuretics are used.
 
The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in awareness among patients, higher number of target population, rise in demand for PMS drugs, and easy availability of drugs. In addition, campaigns from government and non-government organizations to elevate female health status and education supports the market growth. However, unknown etiology and pathophysiology of PMS is anticipated to hamper the market growth.
 
The global premenstrual syndrome treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, it is classified into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Based on type market is classified as prescription and OTC. According to distribution channel, the market is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
 
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of major four geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Type
Analgesics
Antidepressants
Oral Contraceptives & Ovarian Suppression Agents
Others
 
Type
Prescription
OTC
 
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers
 
By Region
 
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
ABBVIE INC.
AstraZeneca plc.
BASF Corporation
Bayer AG
Dr. Reddy's Laboratories Ltd
Eli Lilly And Company
GlaxoSmithKline Plc
H. Lundbeck A/S
Pfizer Inc
Shionogi Inc
 
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Teva Pharmaceutical Industries Ltd.
Allergan PLC
READ MORE

Table Of Content

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

 

1.3.1. List of Key Players Profiled In The Report

 

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Key Findings

 

2.2.1. Top Investment Pockets

2.2.2. Top Player Positioning, 2018

 

2.3. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Forces Shaping Premenstrual Syndrome Treatment Industry/Market

 

3.2.1. Moderate Power of Suppliers

3.2.2. Moderate Threat of New Entrants

3.2.3. Low Threat of Substitution

3.2.4. Moderate Competitive Rivalry

3.2.5. Moderate Bargaining Power of Buyers

 

3.3. Market Dynamics

 

3.3.1. Drivers

 

3.3.1.1. Increase In Prevalence of Pms

3.3.1.2. Growth In Awareness For Pms Therapeutics

3.3.1.3. Surge In Healthcare Expenditure Worldwide

 

3.3.2. Restraint

 

3.3.2.1. Poor Demand In Under Developed Countries

 

3.3.3. Opportunities

 

3.3.3.1. Growth Opportunities In Emerging Markets

3.3.3.2. Higher Number of Unmet Needs For Treatment of Pms

 

3.3.4. Impact Analysis

 

Chapter 4: Premenstrual Syndrome Treatment Market, By Drug Type

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Analgesics

 

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis, By Country

 

4.3. Antidepressants

 

4.3.1. Key Market Trends And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis, By Country

 

4.4. Oral Contraceptives & Ovarian Suppression Agents

 

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis, By Country

 

4.5. Others

 

4.5.1. Key Market Trends And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis, By Country

 

Chapter 5: Premenstrual Syndrome Treatment Market, By Type.

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Prescription

 

5.2.1. Market Size And Forecast, By Region

5.2.2. Market Analysis, By Country

 

5.3. Otc

 

5.3.1. Market Size And Forecast, By Region

5.3.2. Market Analysis, By Country

 

Chapter 6: Premenstrual Syndrome Treatment Market, By Distribution Channel

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. Hospitals Pharmacies

 

6.2.1. Market Size And Forecast

6.2.2. Market Analysis, By Country

 

6.3. Drug Stores & Retail Pharmacies

 

6.3.1. Market Size And Forecast

6.3.2. Market Analysis, By Country

 

6.4. Online Pharmacies

 

6.4.1. Market Size And Forecast

6.4.2. Market Analysis, By Country

 

Chapter 7: Premenstrual Syndrome Treatment Market, By Region

 

7.1. Overview

 

7.1.1. Market Size And Forecast

 

7.2. North America

 

7.2.1. Key Market Trends, Growth Factors, And Opportunities

7.2.2. Market Size And Forecast, By Country

 

7.2.2.1. U.S.

 

7.2.2.1.1. U.S. Premenstrual Syndrome Treatment Market, By Drug Type

7.2.2.1.2. U.S. Premenstrual Syndrome Treatment Market, By Type

7.2.2.1.3. U.S. Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.2.2.2. Canada

 

7.2.2.2.1. Canada Premenstrual Syndrome Treatment Market, By Drug Type

7.2.2.2.2. Canada Premenstrual Syndrome Treatment Market, By Type

7.2.2.2.3. Canada Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.2.2.3. Mexico

 

7.2.2.3.1. Mexico Premenstrual Syndrome Treatment Market, By Drug Type

7.2.2.3.2. Mexico Premenstrual Syndrome Treatment Market, By Type

7.2.2.3.3. Mexico Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.2.3. North America Market Size And Forecast, By Drug Type

7.2.4. North America Premenstrual Syndrome Treatment Market, By Type

7.2.5. North America Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3. Europe

 

7.3.1. Key Market Trends, Growth Factors, And Opportunities

7.3.2. Market Size And Forecast, By Country

 

7.3.2.1. Germany

 

7.3.2.1.1. Germany Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.1.2. Germany Premenstrual Syndrome Treatment Market, By Type

7.3.2.1.3. Germany Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.2. France

 

7.3.2.2.1. France Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.2.2. France Premenstrual Syndrome Treatment Market, By Type

7.3.2.2.3. France Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.3. Uk

 

7.3.2.3.1. Uk Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.3.2. Uk Premenstrual Syndrome Treatment Market, By Type

7.3.2.3.3. Uk Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.4. Italy

 

7.3.2.4.1. Italy Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.4.2. Italy Premenstrual Syndrome Treatment Market, By Type

7.3.2.4.3. Italy Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.5. Spain

 

7.3.2.5.1. Spain Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.5.2. Spain Premenstrual Syndrome Treatment Market, By Type

7.3.2.5.3. Spain Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.6. Rest of Europe

 

7.3.2.6.1. Rest of Europe Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.6.2. Rest of Europe Premenstrual Syndrome Treatment Market, By Type

7.3.2.6.3. Rest of Europe Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.3. Europe Market Size And Forecast, By Drug Type

7.3.4. Europe Premenstrual Syndrome Treatment Market, By Type

7.3.5. Europe Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4. Asia-Pacific

 

7.4.1. Key Market Trends, Growth Factors, And Opportunities

7.4.2. Market Size And Forecast, By Country

 

7.4.2.1. Japan

 

7.4.2.1.1. Japan Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.1.2. Japan Premenstrual Syndrome Treatment Market, By Type

7.4.2.1.3. Japan Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.2. China

 

7.4.2.2.1. China Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.2.2. China Premenstrual Syndrome Treatment Market, By Type

7.4.2.2.3. China Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.3. Australia

 

7.4.2.3.1. Australia Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.3.2. Australia Premenstrual Syndrome Treatment Market, By Type

7.4.2.3.3. Australia Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.4. India

 

7.4.2.4.1. India Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.4.2. India Premenstrual Syndrome Treatment Market, By Type

7.4.2.4.3. India Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.5. South Korea

 

7.4.2.5.1. South Korea Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.5.2. South Korea Premenstrual Syndrome Treatment Market, By Type

7.4.2.5.3. South Korea Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.6. Rest of Asia-Pacific

 

7.4.2.6.1. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.6.2. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Type

7.4.2.6.3. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.3. Asia-Pacific Market Size And Forecast, By Drug Type

7.4.4. Asia-Pacific Premenstrual Syndrome Treatment Market, By Type

7.4.5. Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5. Lamea

 

7.5.1. Key Market Trends, Growth Factors, And Opportunities

7.5.2. Market Size And Forecast, By Country

 

7.5.2.1. Brazil

 

7.5.2.1.1. Brazil Premenstrual Syndrome Treatment Market, By Drug Type

7.5.2.1.2. Brazil Premenstrual Syndrome Treatment Market, By Type

7.5.2.1.3. Brazil Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5.2.2. Saudi Arabia

 

7.5.2.2.1. Saudi Arabia Premenstrual Syndrome Treatment Market, By Drug Type

7.5.2.2.2. Saudi Arabia Premenstrual Syndrome Treatment Market, By Type

7.5.2.2.3. Saudi Arabia Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5.2.3. South Africa

 

7.5.2.3.1. South Africa Premenstrual Syndrome Treatment Market, By Drug Type

7.5.2.3.2. South Africa Premenstrual Syndrome Treatment Market, By Type

7.5.2.3.3. South Africa Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5.2.4. Rest of Lamea

 

7.5.2.4.1. Rest of Lamea Premenstrual Syndrome Treatment Market, By Drug Type

7.5.2.4.2. Rest of Lamea Premenstrual Syndrome Treatment Market, By Type

7.5.2.4.3. Rest of Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5.3. Lamea Market Size And Forecast, By Drug Type

7.5.4. Lamea Premenstrual Syndrome Treatment Market, By Type

7.5.5. Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel

 

Chapter 8: Company Profiles

 

8.1. Abbvie Inc.

 

8.1.1. Company Overview

8.1.2. Company Snapshot

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Business Performance

 

8.2. Astrazeneca Plc

 

8.2.1. Company Overview

8.2.2. Company Snapshot

8.2.3. Operating Business Segments

8.2.4. Product Portfolio

8.2.5. Business Performance

8.2.6. Key Strategic Moves And Developments

 

8.3. Basf Corporation

 

8.3.1. Company Overview

8.3.2. Company Snapshot

8.3.3. Operating Business Segments

8.3.4. Product Portfolio

8.3.5. Business Performance

 

8.4. Bayer Ag.

 

8.4.1. Company Overview

8.4.2. Operating Business Segments

8.4.3. Product Portfolio

8.4.4. Business Performance

 

8.5. Dr. Reddy�S Laboratories Ltd

 

8.5.1. Company Overview

8.5.2. Company Snapshot

8.5.3. Operating Business Segments

8.5.4. Product Portfolio

8.5.5. Business Performance

 

8.6. Eli Lilly And Company.

 

8.6.1. Company Overview

8.6.2. Company Snapshot

8.6.3. Operating Business Segments

8.6.4. Product Portfolio

8.6.5. Business Performance

 

8.7. Glaxosmithkline Plc.

 

8.7.1. Company Overview

8.7.2. Company Snapshot

8.7.3. Operating Business Segments

8.7.4. Product Portfolio

8.7.5. Business Performance

 

8.8. H. Lundbeck A/S

 

8.8.1. Company Overview

8.8.2. Company Snapshot

8.8.3. Operating Business Segments

8.8.4. Product Portfolio

8.8.5. Business Performance

 

8.9. Pfizer Inc.

 

8.9.1. Company Overview

8.9.2. Company Snapshot

8.9.3. Operating Business Segments

8.9.4. Product Portfolio

8.9.5. Business Performance

 

8.10. Shionogi Inc.

 

8.10.1. Company Overview

8.10.2. Operating Business Segments

8.10.3. Product Portfolio

8.10.4. Business Performance


List Of Figure

List of Figures

 

Figure 01. Top Investment Pockets

Figure 02. Top Player Positioning, 2018

Figure 03. Global Premenstrual Syndrome Treatment Market Segmentation

Figure 04. Impact Analysis

Figure 05. Comparative Analysis of Analgesics Market, By Country, 2018 & 2026 (USD Million)

Figure 06. Comparative Analysis of Antidepressants Market, By Country, 2018 & 2026 (USD Million)

Figure 07. Comparative Analysis of Oral Contraceptives & Ovarian Suppression Agents Market, By Country, 2018 & 2026 (USD Million)

Figure 08. Comparative Analysis of Others Market, By Country, 2018 & 2026 (USD Million)

Figure 09. Comparative Analysis of Prescription Premenstrual Syndrome Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 10. Comparative Analysis of Otc Premenstrual Syndrome Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 11. Comparative Analysis of Premenstrual Syndrome Treatment Market For Hospitals Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 12. Comparative Analysis of Premenstrual Syndrome Treatment Market For Drug Stores & Retail Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 13. Comparative Analysis of Premenstrual Syndrome Treatment Market For Online Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 14. U.S. Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 15. Canada Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 16. Mexico Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 17. Germany Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 18. France Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 19. Uk Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 20. Italy Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 21. Spain Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 22. Rest of Europe Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 23. Japan Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 24. China Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 25. Australia Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 26. India Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 27. South Korea Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 28. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 29. Brazil Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 30. Saudi Arabia Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 31. South Africa Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 32. Rest of Lamea Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 33. Abbvie: Net Sales, 2016-2018 (USD Million)

Figure 34. Abbvie: Revenue Share By Region, 2018(%)

Figure 35. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 36. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 37. Basf: Net Sales, 2016-2018 (USD Million)

Figure 38. Basf: Revenue Share By Segment, 2018(%)

Figure 39. Basf: Revenue Share By Region, 2018(%)

Figure 40. Bayer: Net Sales, 2016-2018 (USD Million)

Figure 41. Bayer.: Revenue Share By Segment, 2018 (%)

Figure 42. Bayer.: Revenue Share By Region, 2018(%)

Figure 43. Dr. Reddy'S: Net Sales, 2016-2018 (USD Million)

Figure 44. Dr. Reddy'S: Revenue Share By Segment, 2018 (%)

Figure 45. Dr. Reddy'S: Revenue Share By Region, 2018(%)

Figure 46. Lilly: Net Sales, 2016-2018 (USD Million)

Figure 47. Lilly: Revenue Share By Segment, 2018 (%)

Figure 48. Lilly: Revenue Share By Region, 2018(%)

Figure 49. Gsk: Net Sales, 2016-2018 (USD Million)

Figure 50. Gsk: Revenue Share By Segment, 2018(%)

Figure 51. Gsk: Revenue Share By Region, 2018(%)

Figure 52. Lundbeck: Net Sales, 2016-2018 (USD Million)

Figure 53. Lundbeck: Revenue Share By Segment, 2018 (%)

Figure 54. Lundbeck: Revenue Share By Region, 2018(%)

Figure 55. Pfizer: Net Sales, 2016-2018 (USD Million)

Figure 56. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 57. Pfizer: Revenue Share By Region, 2018(%)

Figure 58. Shionogi: Net Sales, 2016-2018 (USD Million)

Figure 59. Shionogi: Revenue Share By Region, 2018(%)

Figure 60. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 61. Sanofi: Revenue Share By Region, 2018(%)


List Of Table

List of Tables

 

Table 01. Global Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026 (USD Million)

Table 02. Analgesics Market, By Region, 2018-2026 (USD Million)

Table 03. Antidepressants Market, By Region, 2018-2026 (USD Million)

Table 04. Oral Contraceptives & Ovarian Suppression Agents Market, By Region, 2018-2026 (USD Million)

Table 05. Others Market, By Region, 2018-2026 (USD Million)

Table 06. Global Premenstrual Syndrome Treatment Market, By Type, 2018-2026 (USD Million)

Table 07. Prescription Premenstrual Syndrome Treatment Market, By Region, 2018-2026 (USD Million)

Table 08. Otc Premenstrual Syndrome Treatment Market, By Region, 2018-2026 (USD Million)

Table 09. Global Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026 (USD Million)

Table 10. Premenstrual Syndrome Treatment Market For Hospitals Pharmacies, By Region, 2018-2026 (USD Million)

Table 11. Premenstrual Syndrome Treatment Market For Drug Stores & Retail Pharmacies, By Region, 2018-2026 (USD Million)

Table 12. Premenstrual Syndrome Treatment Market For Online Pharmacies, By Region, 2018-2026 (USD Million)

Table 13. Premenstrual Syndrome Treatment Market Revenue, By Region, 2018-2026 (USD Million)

Table 14. North America Premenstrual Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 15. U.S. Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 16. U.S. Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 17. U.S. Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 18. Canada Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 19. Canada Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 20. Canada Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 21. Mexico Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 22. Mexico Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 23. Mexico Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 24. North America Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 25. North America Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 26. North America Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 27. Europe Premenstrual Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 28. Germany Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 29. Germany Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 30. Germany Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 31. France Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 32. France Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 33. France Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 34. Uk Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 35. Uk Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 36. Uk Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 37. Italy Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 38. Italy Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 39. Italy Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 40. Spain Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 41. Spain Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 42. Spain Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 43. Rest of Europe Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 44. Rest of Europe Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 45. Rest of Europe Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 46. Europe Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 47. Europe Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 48. Europe Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 49. Asia-Pacific Premenstrual Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 50. Japan Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 51. Japan Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 52. Japan Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 53. China Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 54. China Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 55. China Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 56. Australia Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 57. Australia Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 58. Australia Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 59. India Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 60. India Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 61. India Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 62. South Korea Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 63. South Korea Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 64. South Korea Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 65. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 66. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 67. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 68. Asia-Pacific Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 69. Asia-Pacific Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 70. Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 71. Lamea Premenstrual Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 72. Brazil Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 73. Brazil Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 74. Brazil Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 75. Saudi Arabia Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 76. Saudi Arabia Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 77. Saudi Arabia Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 78. South Africa Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 79. South Afria Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 80. South Africa Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 81. Rest of Lamea Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 82. Rest of Lamea Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 83. Rest of Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 84. Lamea Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 85. Lamea Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 86. Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 87. Abbvie: Company Snapshot

Table 88. Abbvie: Operating Business Segments

Table 89. Abbvie: Product Portfolio

Table 90. Astrazeneca: Company Snapshot

Table 91. Astrazeneca: Operating Business Segments

Table 92. Astrazeneca: Product Portfolio

Table 93. Basf: Company Snapshot

Table 94. Basf: Operating Segments

Table 95. Basf: Product Portfolio

Table 96. Bayer.: Company Snapshot

Table 97. Bayer.: Operating Segments

Table 98. Bayer.: Product Portfolio

Table 99. Dr. Reddy'S: Company Snapshot

Table 100. Dr. Reddy'S: Operating Business Segments

Table 101. Dr. Reddy'S: Product Portfolio

Table 102. Lilly: Company Snapshot

Table 103. Lilly: Operating Segments

Table 104. Lilly: Product Portfolio

Table 105. Gsk: Company Snapshot

Table 106. Gsk: Operating Business Segments

Table 107. Gsk: Product Portfolio

Table 108. Lundbeck: Company Snapshot

Table 109. Lundbeck: Operating Business Segments

Table 110. Lundbeck: Product Portfolio

Table 111. Pfizer: Company Snapshot

Table 112. Pfizer: Operating Segments

Table 113. Pfizer: Product Portfolio

Table 114. Shionogi: Company Snapshot

Table 115. Shionogi: Operating Business Segments

Table 116. Shionogi: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

ABBVIE INC., AstraZeneca plc., BASF Corporation, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly And Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., and Shionogi Inc.

Company Profile

Company Profile Title

The global premenstrual syndrome treatment market was valued at USD 1,129 million in 2018, and is projected to reach USD 1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026.
 
Premenstrual syndrome or PMS refers to physical & emotional symptoms, which occur one to two weeks before the initiation of woman's menses. It is characterized by symptoms such as acne, tender breasts, mood swings, bloating, fatigue, and irritability. Lifestyle changes are anticipated to help relieve PMS symptoms. However, based on the severity of symptoms, different types of drugs such as analgesics, antidepressants, and diuretics are used.
 
The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in awareness among patients, higher number of target population, rise in demand for PMS drugs, and easy availability of drugs. In addition, campaigns from government and non-government organizations to elevate female health status and education supports the market growth. However, unknown etiology and pathophysiology of PMS is anticipated to hamper the market growth.
 
The global premenstrual syndrome treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, it is classified into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Based on type market is classified as prescription and OTC. According to distribution channel, the market is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
 
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of major four geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Type
Analgesics
Antidepressants
Oral Contraceptives & Ovarian Suppression Agents
Others
 
Type
Prescription
OTC
 
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers
 
By Region
 
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
ABBVIE INC.
AstraZeneca plc.
BASF Corporation
Bayer AG
Dr. Reddy's Laboratories Ltd
Eli Lilly And Company
GlaxoSmithKline Plc
H. Lundbeck A/S
Pfizer Inc
Shionogi Inc
 
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Teva Pharmaceutical Industries Ltd.
Allergan PLC
READ MORE

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

 

1.3.1. List of Key Players Profiled In The Report

 

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Key Findings

 

2.2.1. Top Investment Pockets

2.2.2. Top Player Positioning, 2018

 

2.3. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Forces Shaping Premenstrual Syndrome Treatment Industry/Market

 

3.2.1. Moderate Power of Suppliers

3.2.2. Moderate Threat of New Entrants

3.2.3. Low Threat of Substitution

3.2.4. Moderate Competitive Rivalry

3.2.5. Moderate Bargaining Power of Buyers

 

3.3. Market Dynamics

 

3.3.1. Drivers

 

3.3.1.1. Increase In Prevalence of Pms

3.3.1.2. Growth In Awareness For Pms Therapeutics

3.3.1.3. Surge In Healthcare Expenditure Worldwide

 

3.3.2. Restraint

 

3.3.2.1. Poor Demand In Under Developed Countries

 

3.3.3. Opportunities

 

3.3.3.1. Growth Opportunities In Emerging Markets

3.3.3.2. Higher Number of Unmet Needs For Treatment of Pms

 

3.3.4. Impact Analysis

 

Chapter 4: Premenstrual Syndrome Treatment Market, By Drug Type

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Analgesics

 

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis, By Country

 

4.3. Antidepressants

 

4.3.1. Key Market Trends And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis, By Country

 

4.4. Oral Contraceptives & Ovarian Suppression Agents

 

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis, By Country

 

4.5. Others

 

4.5.1. Key Market Trends And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis, By Country

 

Chapter 5: Premenstrual Syndrome Treatment Market, By Type.

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Prescription

 

5.2.1. Market Size And Forecast, By Region

5.2.2. Market Analysis, By Country

 

5.3. Otc

 

5.3.1. Market Size And Forecast, By Region

5.3.2. Market Analysis, By Country

 

Chapter 6: Premenstrual Syndrome Treatment Market, By Distribution Channel

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. Hospitals Pharmacies

 

6.2.1. Market Size And Forecast

6.2.2. Market Analysis, By Country

 

6.3. Drug Stores & Retail Pharmacies

 

6.3.1. Market Size And Forecast

6.3.2. Market Analysis, By Country

 

6.4. Online Pharmacies

 

6.4.1. Market Size And Forecast

6.4.2. Market Analysis, By Country

 

Chapter 7: Premenstrual Syndrome Treatment Market, By Region

 

7.1. Overview

 

7.1.1. Market Size And Forecast

 

7.2. North America

 

7.2.1. Key Market Trends, Growth Factors, And Opportunities

7.2.2. Market Size And Forecast, By Country

 

7.2.2.1. U.S.

 

7.2.2.1.1. U.S. Premenstrual Syndrome Treatment Market, By Drug Type

7.2.2.1.2. U.S. Premenstrual Syndrome Treatment Market, By Type

7.2.2.1.3. U.S. Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.2.2.2. Canada

 

7.2.2.2.1. Canada Premenstrual Syndrome Treatment Market, By Drug Type

7.2.2.2.2. Canada Premenstrual Syndrome Treatment Market, By Type

7.2.2.2.3. Canada Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.2.2.3. Mexico

 

7.2.2.3.1. Mexico Premenstrual Syndrome Treatment Market, By Drug Type

7.2.2.3.2. Mexico Premenstrual Syndrome Treatment Market, By Type

7.2.2.3.3. Mexico Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.2.3. North America Market Size And Forecast, By Drug Type

7.2.4. North America Premenstrual Syndrome Treatment Market, By Type

7.2.5. North America Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3. Europe

 

7.3.1. Key Market Trends, Growth Factors, And Opportunities

7.3.2. Market Size And Forecast, By Country

 

7.3.2.1. Germany

 

7.3.2.1.1. Germany Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.1.2. Germany Premenstrual Syndrome Treatment Market, By Type

7.3.2.1.3. Germany Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.2. France

 

7.3.2.2.1. France Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.2.2. France Premenstrual Syndrome Treatment Market, By Type

7.3.2.2.3. France Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.3. Uk

 

7.3.2.3.1. Uk Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.3.2. Uk Premenstrual Syndrome Treatment Market, By Type

7.3.2.3.3. Uk Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.4. Italy

 

7.3.2.4.1. Italy Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.4.2. Italy Premenstrual Syndrome Treatment Market, By Type

7.3.2.4.3. Italy Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.5. Spain

 

7.3.2.5.1. Spain Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.5.2. Spain Premenstrual Syndrome Treatment Market, By Type

7.3.2.5.3. Spain Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.2.6. Rest of Europe

 

7.3.2.6.1. Rest of Europe Premenstrual Syndrome Treatment Market, By Drug Type

7.3.2.6.2. Rest of Europe Premenstrual Syndrome Treatment Market, By Type

7.3.2.6.3. Rest of Europe Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.3.3. Europe Market Size And Forecast, By Drug Type

7.3.4. Europe Premenstrual Syndrome Treatment Market, By Type

7.3.5. Europe Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4. Asia-Pacific

 

7.4.1. Key Market Trends, Growth Factors, And Opportunities

7.4.2. Market Size And Forecast, By Country

 

7.4.2.1. Japan

 

7.4.2.1.1. Japan Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.1.2. Japan Premenstrual Syndrome Treatment Market, By Type

7.4.2.1.3. Japan Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.2. China

 

7.4.2.2.1. China Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.2.2. China Premenstrual Syndrome Treatment Market, By Type

7.4.2.2.3. China Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.3. Australia

 

7.4.2.3.1. Australia Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.3.2. Australia Premenstrual Syndrome Treatment Market, By Type

7.4.2.3.3. Australia Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.4. India

 

7.4.2.4.1. India Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.4.2. India Premenstrual Syndrome Treatment Market, By Type

7.4.2.4.3. India Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.5. South Korea

 

7.4.2.5.1. South Korea Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.5.2. South Korea Premenstrual Syndrome Treatment Market, By Type

7.4.2.5.3. South Korea Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.2.6. Rest of Asia-Pacific

 

7.4.2.6.1. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Drug Type

7.4.2.6.2. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Type

7.4.2.6.3. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.4.3. Asia-Pacific Market Size And Forecast, By Drug Type

7.4.4. Asia-Pacific Premenstrual Syndrome Treatment Market, By Type

7.4.5. Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5. Lamea

 

7.5.1. Key Market Trends, Growth Factors, And Opportunities

7.5.2. Market Size And Forecast, By Country

 

7.5.2.1. Brazil

 

7.5.2.1.1. Brazil Premenstrual Syndrome Treatment Market, By Drug Type

7.5.2.1.2. Brazil Premenstrual Syndrome Treatment Market, By Type

7.5.2.1.3. Brazil Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5.2.2. Saudi Arabia

 

7.5.2.2.1. Saudi Arabia Premenstrual Syndrome Treatment Market, By Drug Type

7.5.2.2.2. Saudi Arabia Premenstrual Syndrome Treatment Market, By Type

7.5.2.2.3. Saudi Arabia Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5.2.3. South Africa

 

7.5.2.3.1. South Africa Premenstrual Syndrome Treatment Market, By Drug Type

7.5.2.3.2. South Africa Premenstrual Syndrome Treatment Market, By Type

7.5.2.3.3. South Africa Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5.2.4. Rest of Lamea

 

7.5.2.4.1. Rest of Lamea Premenstrual Syndrome Treatment Market, By Drug Type

7.5.2.4.2. Rest of Lamea Premenstrual Syndrome Treatment Market, By Type

7.5.2.4.3. Rest of Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel

 

7.5.3. Lamea Market Size And Forecast, By Drug Type

7.5.4. Lamea Premenstrual Syndrome Treatment Market, By Type

7.5.5. Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel

 

Chapter 8: Company Profiles

 

8.1. Abbvie Inc.

 

8.1.1. Company Overview

8.1.2. Company Snapshot

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Business Performance

 

8.2. Astrazeneca Plc

 

8.2.1. Company Overview

8.2.2. Company Snapshot

8.2.3. Operating Business Segments

8.2.4. Product Portfolio

8.2.5. Business Performance

8.2.6. Key Strategic Moves And Developments

 

8.3. Basf Corporation

 

8.3.1. Company Overview

8.3.2. Company Snapshot

8.3.3. Operating Business Segments

8.3.4. Product Portfolio

8.3.5. Business Performance

 

8.4. Bayer Ag.

 

8.4.1. Company Overview

8.4.2. Operating Business Segments

8.4.3. Product Portfolio

8.4.4. Business Performance

 

8.5. Dr. Reddy�S Laboratories Ltd

 

8.5.1. Company Overview

8.5.2. Company Snapshot

8.5.3. Operating Business Segments

8.5.4. Product Portfolio

8.5.5. Business Performance

 

8.6. Eli Lilly And Company.

 

8.6.1. Company Overview

8.6.2. Company Snapshot

8.6.3. Operating Business Segments

8.6.4. Product Portfolio

8.6.5. Business Performance

 

8.7. Glaxosmithkline Plc.

 

8.7.1. Company Overview

8.7.2. Company Snapshot

8.7.3. Operating Business Segments

8.7.4. Product Portfolio

8.7.5. Business Performance

 

8.8. H. Lundbeck A/S

 

8.8.1. Company Overview

8.8.2. Company Snapshot

8.8.3. Operating Business Segments

8.8.4. Product Portfolio

8.8.5. Business Performance

 

8.9. Pfizer Inc.

 

8.9.1. Company Overview

8.9.2. Company Snapshot

8.9.3. Operating Business Segments

8.9.4. Product Portfolio

8.9.5. Business Performance

 

8.10. Shionogi Inc.

 

8.10.1. Company Overview

8.10.2. Operating Business Segments

8.10.3. Product Portfolio

8.10.4. Business Performance


List Of Figure

List of Figures

 

Figure 01. Top Investment Pockets

Figure 02. Top Player Positioning, 2018

Figure 03. Global Premenstrual Syndrome Treatment Market Segmentation

Figure 04. Impact Analysis

Figure 05. Comparative Analysis of Analgesics Market, By Country, 2018 & 2026 (USD Million)

Figure 06. Comparative Analysis of Antidepressants Market, By Country, 2018 & 2026 (USD Million)

Figure 07. Comparative Analysis of Oral Contraceptives & Ovarian Suppression Agents Market, By Country, 2018 & 2026 (USD Million)

Figure 08. Comparative Analysis of Others Market, By Country, 2018 & 2026 (USD Million)

Figure 09. Comparative Analysis of Prescription Premenstrual Syndrome Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 10. Comparative Analysis of Otc Premenstrual Syndrome Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 11. Comparative Analysis of Premenstrual Syndrome Treatment Market For Hospitals Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 12. Comparative Analysis of Premenstrual Syndrome Treatment Market For Drug Stores & Retail Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 13. Comparative Analysis of Premenstrual Syndrome Treatment Market For Online Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 14. U.S. Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 15. Canada Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 16. Mexico Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 17. Germany Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 18. France Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 19. Uk Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 20. Italy Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 21. Spain Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 22. Rest of Europe Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 23. Japan Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 24. China Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 25. Australia Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 26. India Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 27. South Korea Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 28. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 29. Brazil Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 30. Saudi Arabia Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 31. South Africa Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 32. Rest of Lamea Premenstrual Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 33. Abbvie: Net Sales, 2016-2018 (USD Million)

Figure 34. Abbvie: Revenue Share By Region, 2018(%)

Figure 35. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 36. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 37. Basf: Net Sales, 2016-2018 (USD Million)

Figure 38. Basf: Revenue Share By Segment, 2018(%)

Figure 39. Basf: Revenue Share By Region, 2018(%)

Figure 40. Bayer: Net Sales, 2016-2018 (USD Million)

Figure 41. Bayer.: Revenue Share By Segment, 2018 (%)

Figure 42. Bayer.: Revenue Share By Region, 2018(%)

Figure 43. Dr. Reddy'S: Net Sales, 2016-2018 (USD Million)

Figure 44. Dr. Reddy'S: Revenue Share By Segment, 2018 (%)

Figure 45. Dr. Reddy'S: Revenue Share By Region, 2018(%)

Figure 46. Lilly: Net Sales, 2016-2018 (USD Million)

Figure 47. Lilly: Revenue Share By Segment, 2018 (%)

Figure 48. Lilly: Revenue Share By Region, 2018(%)

Figure 49. Gsk: Net Sales, 2016-2018 (USD Million)

Figure 50. Gsk: Revenue Share By Segment, 2018(%)

Figure 51. Gsk: Revenue Share By Region, 2018(%)

Figure 52. Lundbeck: Net Sales, 2016-2018 (USD Million)

Figure 53. Lundbeck: Revenue Share By Segment, 2018 (%)

Figure 54. Lundbeck: Revenue Share By Region, 2018(%)

Figure 55. Pfizer: Net Sales, 2016-2018 (USD Million)

Figure 56. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 57. Pfizer: Revenue Share By Region, 2018(%)

Figure 58. Shionogi: Net Sales, 2016-2018 (USD Million)

Figure 59. Shionogi: Revenue Share By Region, 2018(%)

Figure 60. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 61. Sanofi: Revenue Share By Region, 2018(%)


List Of Table

List of Tables

 

Table 01. Global Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026 (USD Million)

Table 02. Analgesics Market, By Region, 2018-2026 (USD Million)

Table 03. Antidepressants Market, By Region, 2018-2026 (USD Million)

Table 04. Oral Contraceptives & Ovarian Suppression Agents Market, By Region, 2018-2026 (USD Million)

Table 05. Others Market, By Region, 2018-2026 (USD Million)

Table 06. Global Premenstrual Syndrome Treatment Market, By Type, 2018-2026 (USD Million)

Table 07. Prescription Premenstrual Syndrome Treatment Market, By Region, 2018-2026 (USD Million)

Table 08. Otc Premenstrual Syndrome Treatment Market, By Region, 2018-2026 (USD Million)

Table 09. Global Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026 (USD Million)

Table 10. Premenstrual Syndrome Treatment Market For Hospitals Pharmacies, By Region, 2018-2026 (USD Million)

Table 11. Premenstrual Syndrome Treatment Market For Drug Stores & Retail Pharmacies, By Region, 2018-2026 (USD Million)

Table 12. Premenstrual Syndrome Treatment Market For Online Pharmacies, By Region, 2018-2026 (USD Million)

Table 13. Premenstrual Syndrome Treatment Market Revenue, By Region, 2018-2026 (USD Million)

Table 14. North America Premenstrual Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 15. U.S. Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 16. U.S. Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 17. U.S. Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 18. Canada Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 19. Canada Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 20. Canada Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 21. Mexico Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 22. Mexico Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 23. Mexico Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 24. North America Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 25. North America Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 26. North America Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 27. Europe Premenstrual Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 28. Germany Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 29. Germany Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 30. Germany Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 31. France Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 32. France Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 33. France Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 34. Uk Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 35. Uk Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 36. Uk Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 37. Italy Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 38. Italy Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 39. Italy Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 40. Spain Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 41. Spain Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 42. Spain Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 43. Rest of Europe Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 44. Rest of Europe Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 45. Rest of Europe Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 46. Europe Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 47. Europe Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 48. Europe Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 49. Asia-Pacific Premenstrual Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 50. Japan Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 51. Japan Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 52. Japan Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 53. China Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 54. China Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 55. China Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 56. Australia Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 57. Australia Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 58. Australia Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 59. India Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 60. India Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 61. India Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 62. South Korea Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 63. South Korea Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 64. South Korea Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 65. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 66. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 67. Rest of Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 68. Asia-Pacific Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 69. Asia-Pacific Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 70. Asia-Pacific Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 71. Lamea Premenstrual Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 72. Brazil Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 73. Brazil Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 74. Brazil Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 75. Saudi Arabia Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 76. Saudi Arabia Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 77. Saudi Arabia Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 78. South Africa Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 79. South Afria Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 80. South Africa Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 81. Rest of Lamea Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 82. Rest of Lamea Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 83. Rest of Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 84. Lamea Premenstrual Syndrome Treatment Market, By Drug Type, 2018-2026

Table 85. Lamea Premenstrual Syndrome Treatment Market, By Type, 2018-2026

Table 86. Lamea Premenstrual Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 87. Abbvie: Company Snapshot

Table 88. Abbvie: Operating Business Segments

Table 89. Abbvie: Product Portfolio

Table 90. Astrazeneca: Company Snapshot

Table 91. Astrazeneca: Operating Business Segments

Table 92. Astrazeneca: Product Portfolio

Table 93. Basf: Company Snapshot

Table 94. Basf: Operating Segments

Table 95. Basf: Product Portfolio

Table 96. Bayer.: Company Snapshot

Table 97. Bayer.: Operating Segments

Table 98. Bayer.: Product Portfolio

Table 99. Dr. Reddy'S: Company Snapshot

Table 100. Dr. Reddy'S: Operating Business Segments

Table 101. Dr. Reddy'S: Product Portfolio

Table 102. Lilly: Company Snapshot

Table 103. Lilly: Operating Segments

Table 104. Lilly: Product Portfolio

Table 105. Gsk: Company Snapshot

Table 106. Gsk: Operating Business Segments

Table 107. Gsk: Product Portfolio

Table 108. Lundbeck: Company Snapshot

Table 109. Lundbeck: Operating Business Segments

Table 110. Lundbeck: Product Portfolio

Table 111. Pfizer: Company Snapshot

Table 112. Pfizer: Operating Segments

Table 113. Pfizer: Product Portfolio

Table 114. Shionogi: Company Snapshot

Table 115. Shionogi: Operating Business Segments

Table 116. Shionogi: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

ABBVIE INC., AstraZeneca plc., BASF Corporation, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly And Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., and Shionogi Inc.